quinta-feira, junho 16, 2011
Poupar não é o mesmo que ganhar
O sr. Costa aprendeu a lição no tempo em que havia escudo, poupar não é o mesmo que ganhar, mas a big-pharma parece que não.
.
"Fat pharma: mechanics of cost-cutting":
.
"This raises the question of whether, across the industry, cost cutting can continue to make up for sluggish sales. Much overhead has already been removed, and expanding into emerging markets, essential for all the global pharmas, will cost money. Cost of goods and research and development expense ratios have mostly stayed put, and it is hard to see why that would change now. If the savings story is petering out, the industry needs revenue growth more than ever. Given that patents will continue to expire, and that developing new products internally has proven hard, expanding the top line may be difficult to do – without still further consolidation"
.
"Fat pharma: mechanics of cost-cutting":
.
"This raises the question of whether, across the industry, cost cutting can continue to make up for sluggish sales. Much overhead has already been removed, and expanding into emerging markets, essential for all the global pharmas, will cost money. Cost of goods and research and development expense ratios have mostly stayed put, and it is hard to see why that would change now. If the savings story is petering out, the industry needs revenue growth more than ever. Given that patents will continue to expire, and that developing new products internally has proven hard, expanding the top line may be difficult to do – without still further consolidation"
Subscrever:
Enviar feedback (Atom)
Sem comentários:
Enviar um comentário